STOCK TITAN

[SCHEDULE 13G] Cabaletta Bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company’s 92.94 million shares outstanding.

Citadel Advisors–managed funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.

Cabaletta Bio (CABA) ha presentato un modulo Schedule 13G rivelando che Citadel Advisors LLC, Citadel Securities LLC, entità correlate e il fondatore Kenneth Griffin possiedono collettivamente 4.818.560 azioni ordinarie, pari a circa il 5,2% delle 92,94 milioni di azioni in circolazione della società.

I fondi gestiti da Citadel Advisors detengono 4.687.280 azioni, mentre l'affiliata di market-making Citadel Securities ne detiene 131.280. Tutti i poteri di voto e dispositivi sono dichiarati come condivisi; nessuna delle persone segnalanti ha autorità esclusiva. La soglia del 5% è stata raggiunta il 12 giugno 2025, facendo scattare l'obbligo di deposito. Non sono inclusi ulteriori risultati finanziari, fattori di rischio o iniziative strategiche.

Cabaletta Bio (CABA) presentó un Schedule 13G revelando que Citadel Advisors LLC, Citadel Securities LLC, entidades relacionadas y el fundador Kenneth Griffin poseen colectivamente 4.818.560 acciones ordinarias, equivalentes a aproximadamente el 5,2% de las 92,94 millones de acciones en circulación de la empresa.

Los fondos gestionados por Citadel Advisors poseen 4.687.280 acciones, mientras que la afiliada de creación de mercado Citadel Securities posee 131.280 acciones. Todo el poder de voto y disposición se reporta como compartido; ninguna de las personas informantes tiene autoridad exclusiva. El umbral del 5% se alcanzó el 12 de junio de 2025, lo que activó la presentación. No se incluyen resultados financieros adicionales, factores de riesgo ni iniciativas estratégicas.

Cabaletta Bio (CABA)는 Schedule 13G를 제출하여 Citadel Advisors LLC, Citadel Securities LLC, 관련 법인 및 창립자 Kenneth Griffin이 총 4,818,560 보통주를 보유하고 있으며, 이는 회사의 92.94백만 주 중 약 5.2%에 해당한다고 공개했습니다.

Citadel Advisors가 관리하는 펀드는 4,687,280주를 보유하고 있으며, 시장 조성 계열사인 Citadel Securities는 131,280주를 보유하고 있습니다. 모든 의결권 및 처분 권한은 공동 보유로 보고되었으며, 보고자 중 어느 누구도 단독 권한을 갖고 있지 않습니다. 5% 임계점은 2025년 6월 12일에 도달하여 제출 의무가 발생했습니다. 추가적인 재무 결과, 위험 요소 또는 전략적 계획은 포함되어 있지 않습니다.

Cabaletta Bio (CABA) a déposé un Schedule 13G révélant que Citadel Advisors LLC, Citadel Securities LLC, des entités liées et le fondateur Kenneth Griffin détiennent collectivement 4 818 560 actions ordinaires, soit environ 5,2 % des 92,94 millions d’actions en circulation de la société.

Les fonds gérés par Citadel Advisors détiennent 4 687 280 actions, tandis que l’affilié de tenue de marché Citadel Securities détient 131 280 actions. Tous les pouvoirs de vote et d’aliénation sont déclarés comme partagés ; aucune des personnes déclarantes ne dispose d’une autorité exclusive. Le seuil de 5 % a été atteint le 12 juin 2025, déclenchant le dépôt. Aucun résultat financier supplémentaire, facteur de risque ou initiative stratégique n’est inclus.

Cabaletta Bio (CABA) hat eine Schedule 13G eingereicht, in der offengelegt wird, dass Citadel Advisors LLC, Citadel Securities LLC, verbundene Unternehmen und Gründer Kenneth Griffin gemeinsam 4.818.560 Stammaktien halten, was etwa 5,2 % der 92,94 Millionen ausstehenden Aktien des Unternehmens entspricht.

Die von Citadel Advisors verwalteten Fonds halten 4.687.280 Aktien, während die marktbildende Tochtergesellschaft Citadel Securities 131.280 Aktien hält. Die Stimm- und Verfügungsgewalt wird als gemeinsam gemeldet; keine der meldenden Personen hat Alleinbefugnis. Die 5 %-Schwelle wurde am 12. Juni 2025 erreicht, was die Meldung auslöste. Es sind keine weiteren Finanzergebnisse, Risikofaktoren oder strategischen Initiativen enthalten.

Positive
  • Citadel affiliates and Kenneth Griffin disclosed a 5.2 % stake (4.82 million shares) in Cabaletta Bio, introducing a high-profile institutional holder.
Negative
  • None.

Insights

TL;DR: Citadel now holds 5.2 % of CABA; passive stake, limited immediate impact.

Citadel Advisors and affiliated vehicles have crossed the 5 % beneficial-ownership line, requiring this Schedule 13G. The filing is made under Rule 13d-1(c), indicating a passive, non-activist position. All 4.82 million shares are subject to shared voting and dispositive power, suggesting coordinated but not unilateral decision-making. While the entrance of a sophisticated hedge fund may improve trading liquidity and spark investor attention, the document contains no plans for operational or governance changes. Consequently, the stake is noteworthy but does not materially alter Cabaletta Bio’s near-term fundamentals or control structure.

TL;DR: Governance framework unchanged; monitor for any shift to 13D.

Schedule 13G signifies a passive ownership intent. The group’s 5.2 % holding is below thresholds that typically secure board seats or trigger anti-takeover provisions. Zero sole voting power means no single entity can act independently, limiting influence on strategic decisions. Should the group increase its position or convert to a Schedule 13D, governance dynamics would warrant reassessment. For now, the filing is informational rather than transformational, keeping corporate control firmly with existing management and shareholders.

Cabaletta Bio (CABA) ha presentato un modulo Schedule 13G rivelando che Citadel Advisors LLC, Citadel Securities LLC, entità correlate e il fondatore Kenneth Griffin possiedono collettivamente 4.818.560 azioni ordinarie, pari a circa il 5,2% delle 92,94 milioni di azioni in circolazione della società.

I fondi gestiti da Citadel Advisors detengono 4.687.280 azioni, mentre l'affiliata di market-making Citadel Securities ne detiene 131.280. Tutti i poteri di voto e dispositivi sono dichiarati come condivisi; nessuna delle persone segnalanti ha autorità esclusiva. La soglia del 5% è stata raggiunta il 12 giugno 2025, facendo scattare l'obbligo di deposito. Non sono inclusi ulteriori risultati finanziari, fattori di rischio o iniziative strategiche.

Cabaletta Bio (CABA) presentó un Schedule 13G revelando que Citadel Advisors LLC, Citadel Securities LLC, entidades relacionadas y el fundador Kenneth Griffin poseen colectivamente 4.818.560 acciones ordinarias, equivalentes a aproximadamente el 5,2% de las 92,94 millones de acciones en circulación de la empresa.

Los fondos gestionados por Citadel Advisors poseen 4.687.280 acciones, mientras que la afiliada de creación de mercado Citadel Securities posee 131.280 acciones. Todo el poder de voto y disposición se reporta como compartido; ninguna de las personas informantes tiene autoridad exclusiva. El umbral del 5% se alcanzó el 12 de junio de 2025, lo que activó la presentación. No se incluyen resultados financieros adicionales, factores de riesgo ni iniciativas estratégicas.

Cabaletta Bio (CABA)는 Schedule 13G를 제출하여 Citadel Advisors LLC, Citadel Securities LLC, 관련 법인 및 창립자 Kenneth Griffin이 총 4,818,560 보통주를 보유하고 있으며, 이는 회사의 92.94백만 주 중 약 5.2%에 해당한다고 공개했습니다.

Citadel Advisors가 관리하는 펀드는 4,687,280주를 보유하고 있으며, 시장 조성 계열사인 Citadel Securities는 131,280주를 보유하고 있습니다. 모든 의결권 및 처분 권한은 공동 보유로 보고되었으며, 보고자 중 어느 누구도 단독 권한을 갖고 있지 않습니다. 5% 임계점은 2025년 6월 12일에 도달하여 제출 의무가 발생했습니다. 추가적인 재무 결과, 위험 요소 또는 전략적 계획은 포함되어 있지 않습니다.

Cabaletta Bio (CABA) a déposé un Schedule 13G révélant que Citadel Advisors LLC, Citadel Securities LLC, des entités liées et le fondateur Kenneth Griffin détiennent collectivement 4 818 560 actions ordinaires, soit environ 5,2 % des 92,94 millions d’actions en circulation de la société.

Les fonds gérés par Citadel Advisors détiennent 4 687 280 actions, tandis que l’affilié de tenue de marché Citadel Securities détient 131 280 actions. Tous les pouvoirs de vote et d’aliénation sont déclarés comme partagés ; aucune des personnes déclarantes ne dispose d’une autorité exclusive. Le seuil de 5 % a été atteint le 12 juin 2025, déclenchant le dépôt. Aucun résultat financier supplémentaire, facteur de risque ou initiative stratégique n’est inclus.

Cabaletta Bio (CABA) hat eine Schedule 13G eingereicht, in der offengelegt wird, dass Citadel Advisors LLC, Citadel Securities LLC, verbundene Unternehmen und Gründer Kenneth Griffin gemeinsam 4.818.560 Stammaktien halten, was etwa 5,2 % der 92,94 Millionen ausstehenden Aktien des Unternehmens entspricht.

Die von Citadel Advisors verwalteten Fonds halten 4.687.280 Aktien, während die marktbildende Tochtergesellschaft Citadel Securities 131.280 Aktien hält. Die Stimm- und Verfügungsgewalt wird als gemeinsam gemeldet; keine der meldenden Personen hat Alleinbefugnis. Die 5 %-Schwelle wurde am 12. Juni 2025 erreicht, was die Meldung auslöste. Es sind keine weiteren Finanzergebnisse, Risikofaktoren oder strategischen Initiativen enthalten.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 92,943,101 Shares outstanding comprised of (i) 89,943,101 Shares outstanding as of immediately following the issuer's public offering (according to the issuer's Prospectus Supplement as filed with the Securities and Exchange Commission on June 12, 2025), and (ii) 3,000,000 Shares issuable upon conversion of certain warrants held by affiliates of the reporting persons. Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on June 20, 2025.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:06/20/2025

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

How many Cabaletta Bio (CABA) shares did Citadel entities report owning?

The Schedule 13G states Citadel-managed funds hold 4,687,280 shares, with shared voting and dispositive power.

What percentage of Cabaletta Bio’s outstanding stock does Citadel’s position represent?

Citadel affiliates reported ownership of approximately 5.0 %; including Kenneth Griffin’s aggregated amount, the stake is 5.2 %.

Who is identified as the ultimate controlling person in the 13G filing?

The filing names Kenneth Griffin as the control person with a beneficial interest in 4,818,560 shares.

Did any Citadel entity report sole voting power over CABA shares?

No. Each reporting person disclosed 0 shares of sole voting power; all authority is shared.

What date triggered the Schedule 13G requirement for Cabaletta Bio?

The event date is June 12, 2025, when the ownership threshold exceeded 5 %.
Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

CABA Latest News

CABA Stock Data

159.20M
88.43M
3.1%
79.62%
13.83%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PHILADELPHIA